Accelerated blood clearance of PEGylated PLGA nanoparticles following repeated injections: Effects of polymer dose, PEG coating, and encapsulated anticancer drug

Pharmaceutical Research

Volumn 30, Issue 4, 2013, Pages 985-995

  Saadati, Roonak ^a   Dadashzadeh, Simin ^a   Abbasian, Zahra ^a   Soleimanjahi, Hoorieh ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

accelerated blood clearance (ABC); anti PEG IgM antibody; etoposide; pharmacokinetics; PLGA PEG nanoparticles

Indexed keywords

DRUG CARRIER; ETOPOSIDE; IMMUNOGLOBULIN M; MACROGOL; MACROGOL ANTIBODY; NANOPARTICLE; POLYGLACTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; ENCAPSULATION; IMMUNOCOMPETENT CELL; MALE; NONHUMAN; PARTICLE SIZE; POLYDISPERSITY INDEX; PRIORITY JOURNAL; RAT; ZETA POTENTIAL;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG CARRIERS; ETOPOSIDE; IMMUNOGLOBULIN M; INJECTIONS, INTRAVENOUS; LACTIC ACID; MALE; NANOPARTICLES; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; RATS; RATS, WISTAR;

EID: 84876502925     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0934-y     Document Type: Article

References (38)

1. Legrand P, Lesieur S, Bochot A, Gref R, Raatjes W, Barratt G, et al. Influence of polymer behaviour in organic solution on the production of polylactide nanoparticles by nanoprecipitation. Int J Pharm. 2007;344(1-2):33-43.
2. Dinarvand R, Sepehri N, Manoochehri S, Rouhani H, Atyabi F. Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomedicine. 2011;6:877-95.
3. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine. 2012;8(2):147-66.
4. Brewer E, Coleman J, Lowman A. Emerging technologies of polymeric nanoparticles in cancer drug delivery. J Nanomaterials. 2011; Article ID 408675, 10 pages.
5. Essa S, Rabanel JM, Hildgen P. Effect of polyethylene glycol (PEG) chain organization on the physicochemical properties of poly(D, L-lactide) (PLA) based nanoparticles. Eur J Pharm Biopharm. 2010;75(2):96-106.
6. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505-15.
7. Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, Harnisch S, et al. 'Stealth' Corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces. 2000;18(3-4):301-13.
8. Danhier F, Lecouturier N, Vroman B, Jerome C, Marchand-Brynaert J, Feron O, et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release. 2009;133(1):11-7.
9. Sharpe M, Easthope SE, Keating GM, Lamb HM. Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma. Drugs. 2002;62(14):2089-126.
10. Dams ET, Laverman P, Oyen WJ, Storm G, Scherphof GL, van Der Meer JW, et al. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther. 2000;292(3):1071-9.
11. Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, van Rooijen N, et al. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther. 2001;298(2):607-12.
12. Ishida T, Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm. 2008;354(1-2):56-62.
13. Dufort S, Sancey L, Coll JL. Physico-chemical parameters that govern nanoparticles fate also dictate rules for their molecular evolution. Adv Drug Deliv Rev. 2012;64(2):179-89.
14. Xu H, Wang KQ, Deng YH, da Chen W. Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes. Biomaterials. 2010;31(17):4757-63.
15. Ma H, Shiraishi K, Minowa T, Kawano K, Yokoyama M, Hattori Y, et al. Accelerated blood clearance was not induced for a gadolinium-containing PEG-poly(L-lysine)-based polymeric micelle in mice. Pharm Res. 2010;27(2):296-302.
16. Gabizon A, Isacson R, Rosengarten O, Tzemach D, Shmeeda H, Sapir R. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of Pegylated liposomal doxorubicin. Cancer Chemother Pharmacol. 2008;61(4):695-702.
17. Ishida T, Atobe K, Wang X, Kiwada H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin- encapsulation and high-dose first injection. J Control Release. 2006;115(3):251-8.
18. Cui J, Li C, Wang C, Li Y, Zhang L, Yang H. Repeated injection of Pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase. J Pharm Pharmacol. 2008;60(12):1651-7.
19. Ma Y, Yang Q, Wang L, Zhou X, Zhao Y, Deng Y. Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats. Eur J Pharm Sci. 2012;45(5):539-45.
20. Koide H, Asai T, Hatanaka K, Urakami T, Ishii T, Kenjo E, et al. Particle size-dependent triggering of accelerated blood clearance phenomenon. Int J Pharm. 2008;362(1-2):197-200.
21. Ishihara T, Takeda M, Sakamoto H, Kimoto A, Kobayashi C, Takasaki N, et al. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm Res. 2009;26(10):2270-9.
22. Saadati R, Dadashzadeh S. Simple and efficient HPLC-UV quantitation of etoposide and its cis-isomer in rat micro-volume plasma and tissue samples: application to pharmacokinetic and biodistribution studies. J Liq Chromatogr Rel Tech. 2011;34(18):2130-48.
23. Shargel L, WU-Pong S, Yu A. Applied Biopharmaceutics & Pharmacokinetics. 5th ed. New York: McGraw Hill; 2005.
24. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53(2):283-318.
25. Torchilin VP, Omelyanenko VG, Papisov MI, Bogdanov Jr AA, Trubetskoy VS, Herron JN, et al. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim Biophys Acta. 1994;1195(1):11-20.
26. Ishida T, Harada M, Wang XY, Ichihara M, Irimura K, Kiwada H. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J Control Release. 2005;105(3):305-17.
27. Ishida T, Maeda R, Ichihara M, Irimura K, Kiwada H. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Control Release. 2003;88(1):35-42.
28. Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release. 2007;122(3):349-55.
29. Wang X, Ishida T, Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release. 2007;119(2):236-44.
30. Ishida T, Ichihara M, Wang X, Kiwada H. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J Control Release. 2006;115(3):243-50.
31. Ishida T, Masuda K, Ichikawa T, Ichihara M, Irimura K, Kiwada H. Accelerated clearance of a second injection of PEGylated liposomes in mice. Int J Pharm. 2003;255(1-2):167-74.
32. Laverman P, Brouwers AH, Dams ET, Oyen WJ, Storm G, van Rooijen N, et al. Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose. J Pharmacol Exp Ther. 2000;293(3):996-1001.
33. Lu W, Wan J, She Z, Jiang X. Brain delivery property and accelerated blood clearance of cationic albumin conjugated Pegylated nanoparticle. J Control Release. 2007;118(1):38-53.
34. Tagami T, Nakamura K, Shimizu T, Ishida T, Kiwada H. Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production. J Control Release. 2009;137(3):234-40.
35. Taguchi K, Urata Y, Anraku M, Watanabe H, Kadowaki D, Sakai H, et al. Hemoglobin vesicles, polyethylene glycol (PEG)ylated liposomes developed as a red blood cell substitute, do not induce the accelerated blood clearance phenomenon in mice. Drug Metab Dispos. 2009;37(11):2197-203.
36. Ishida T, Ichikawa T, Ichihara M, Sadzuka Y, Kiwada H. Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice. J Control Release. 2004;95(3):403-12.
37. Hande KR. Topoisomerase II inhibitors. Update Cancer Ther. 2008;3:13-26.
38. Ishihara T, Maeda T, Sakamoto H, Takasaki N, Shigyo M, Ishida T, et al. Evasion of the accelerated blood clearance phenomenon by coating of nanoparticles with various hydrophilic polymers. Biomacromolecules. 2010;11(10):2700-6.